Cite
MLA Citation
L. Nastoupil et al.. “CHEMO‐FREE TRIPLET COMBINATION OF TGR‐1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL..” Hematological oncology, vol. 35, n.d., pp. 112–113. http://access.bl.uk/ark:/81055/vdc_100047525543.0x00003b